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Advances in genotyping and sequencing technologies have revolutionized the genetics of complex
disease by locating rare and common variants that influence an individual’s risk for diseases, such
as diabetes, cancers, and psychiatric disorders. However, to capitalize on these data for prevention
and therapies requires the identification of causal alleles and a mechanistic understanding for how
these variants contribute to the disease. After discussing the strategies currently used to map
variants for complex diseases, this Primer explores how variants may be prioritized for follow-up
functional studies and the challenges and approaches for assessing the contributions of rare and
common variants to disease phenotypes.Most common diseases are complex: many genetic and environ-
mental factors mediate the risk for developing the disease, and
each individual factor explains only a small proportion of popula-
tion risk (Cardon and Abecasis, 2003). Genome-wide genotyping
with high-throughput approaches has led to the identification of
>2,600 associated common risk alleles, with convincing associ-
ations in >350 different complex traits (most with modest effect
size of odds ratio <1.5) (Hindorff et al., 2009). More recently,
low-cost, high-throughput sequencing of exomes and whole
genomes is giving investigators access to the spectrum of rare
inherited variants and de novo mutations. Once an associated
allele is discovered, a critical step to characterizing pathogen-
esis is the definition of the causal allele, that is the functional
allele that influences disease susceptibility and explains the
observed association. However, for the vast majority of associ-
ated alleles, the identities of causal genes and variants, as well
as the function of these variants, remain uncertain. This Primer
discusses the population genetics features of rare and common
alleles, strategies for connecting these alleles to disease, and
strategies to prioritize them for functional follow-up studies.
Population Genetics of Rare and Common Alleles
Geneticists have long debated the extent to which rare and
common alleles contribute to complex disease (Pritchard,
2001; Pritchard and Cox, 2002; Reich and Lander, 2001).
Although there is evidence of susceptibility alleles across the
frequency spectrum in many complex diseases, it is important
to realize that rare alleles and common alleles have different pop-
ulation characteristics that are relevant to medical genetics.
The exact distinction between rare and common alleles is to an
extent an arbitrary one. We define common alleles as those with
frequencies >1%; these alleles are frequent enough that theycan be queried by genotyping in standard marker panels. Rare
alleles are polymorphic alleles with <1% frequency that might
be most effectively studied with sequencing technologies. The
rarest alleles are seen in only a handful of individuals or are
private to a single individual and can only be observed by
sequencing.
The Origin of Polymorphic Alleles
De novo mutations occurring spontaneously in individuals are
constantly and rapidly introduced into any population. These
mutations are initially ‘‘private’’ to the individual that they
occurred in but might then be passed on to progeny. Most of
these mutations are quickly filtered out or lost by genetic drift
and will never achieve appreciable allele frequencies. I illustrate
this concept by a simulation in which de novo neutral mutations
(conferring no effect on fitness) are introduced into a population
of 2,000 diploid individuals. In 31 generations, 95% of these
mutations disappear from the general population, and not one
of these mutations achieves an allele frequency of >1% in 200
generations (see Figure S1 available online). Mutations that are
deleterious are even more rapidly purged from populations.
Although any de novo mutation is very unlikely to become
a common allele, even a somewhat deleterious mutation may
persist for a few subsequent generations as a rare allele before
disappearing.
Thus populations harbor many rare alleles, most of which
have been derived recently, but relatively few common ones. In
fact, there is only about one common variant on average per
500 bp in European populations (1000 Genomes Project
Consortium, 2010). On the other hand, recent and rapid ex-
pansion of human populations has resulted in the presence
of many rare alleles. At the extreme of the allele frequency
spectrum are de novo mutations; each individual harbors 40Cell 147, September 30, 2011 ª2011 Elsevier Inc. 57
Figure 1. Linkage Disequilibrium and
Haplotype Lengths
(A) Linkage disequilibrium metrics. Left: For two
markers that are random with respect to each
other, each with a 0.5 allele frequency, there is no
linkage between them; each resulting haplotype
has a frequency of 0.25. Middle left: Here the two
markers are not entirely random, and alleles at one
marker correlate partially with alleles at the other
marker. The A allele on the left is observed more
frequently with the C allele on the right, and the T
allele on the left is observed more frequently with
the G allele on the right. Middle right: Here the two
alleles are more tightly linked or have tighter LD
than in the previous case. In this instance, the
presence of the T allele on the left predicts with
certainty the G allele on the right. This could be the
case if the T allele arose de novo on a haplotype
with the G allele on the right Right: For in-
stances of tight LD, an allele at one marker
predicts perfectly the allele at the other marker; in
this case, these two markers form only two
haplotypes.
(B) Changing LD properties of a persistent de novo
mutation. A de novo event (circle), when it
first occurs on a chromosome (bottom), is on one
haplotypic background defined by the chromo-
somal markers on which it forms (red). As gener-
ations pass (moving upward), the event propa-
gates through the population. Recombination
events (Xs) occur, reducing the common haplo-
type (red) on which a variant is present and de-
coupling it from distal markers (blue).
(C) Simulating LD structure of a de novo event as it
becomes a common variant. Here a computer
simulation depicts a chromosome with 10,000
common markers with 1,000 randomly assigned
hot spots. Random mating occurs here with an
average of one recombination event per genera-
tion. A single rare variant is introduced in the
middle of the chromosome on one individual
(bottom) and allowed to propagate through the
population. The left panel depicts the allele fre-
quency as it increases through the generations
(upwards). In the middle panel, all markers in LD
with that variant (with D0 = 1) are indicated with
a red dot. Initially that variant is in LD with every
common marker that it is in phase with on that
chromosome, revealed by the red band stretching
across the bottom of the plot. As random recombination events occur and the allele becomesmore frequent, the number of markers in phase decreases, revealed
by the shrinking red band in the middle. On the right panel, a gray dot indicates markers for which the genotypes correlate with the rare variant (r2 > 0.5). For the
first few generations, there are no other variants that correlate with the de novo mutation as it becomes a rare allele. As time progresses and the allele becomes
more common, it begins to develop genotypic correlations with nearby variants that remain on the same haplotype.de novo point mutations that may not be present in any other
individuals (Conrad et al., 2011).
Common alleles tend to be more ancient than rare ones as it
takes many generations for a rare allele to rise to a reasonable
allele frequency. There are important exceptions to these gener-
alizations. An ancient allele may be rare because it is being
depleted from the population. A common allele may be recent
if it confers a critical survival advantage or has emerged after
a rapid population expansion from a small founder population.
Linkage Disequilibrium and Haplotypes
Genetic linkage is the tendency of alleles at nearby loci to be
transmitted together; two nearby loci are in linkage disequilib-
rium (LD) when recombination events occur between them
very infrequently. Two common metrics quantify pairwise LD
between biallelic markers (see Figure 1A). The R-squared (r2)58 Cell 147, September 30, 2011 ª2011 Elsevier Inc.between two markers is their correlation across chromosomes
within a population. If two markers have r2 = 1, then alleles are
always in phase (or in cis) with each other; in a genetic study,
their association statistics will be identical. The D-prime (D0)
between two markers is inversely related to the fraction of chro-
mosomes that have had historical recombination between them.
If D0 = 1, two biallelic variants constitute only two or three haplo-
types, whereas if D0 < 1, all four possible haplotypes are present
in the population. If D0 = 0 or r2 = 0, then the two markers are
unlinked and statistically independent of each other.
Recombination events break down pairwise linkage between
markers over time and reduce the lengths of haplotypes in a pop-
ulation. Recombination events are much more likely to occur in
hot spot regions in the genome than in other regions (Myers
et al., 2005). As a result, markers without a recombination hot
Figure 2. Common Variants and Fine-
MappingwithConditionalHaplotypeAnalysis
(A) Common variants. This image illustrates the
structure of common variants and LD blocks. The
top lists a reference genome spanning10 kb and
the reference genotypes of the polymorphic vari-
ants. The haplotype structure is broken up into two
blocks by a recombination hot spot. Each block
contains a set of markers in tight LD, which can be
phased into a small number of haplotypes. Below
that, a limitednumberof genotypesaredepicted for
a hypothetical individual because a commercial
array would assay only a limited collection of all of
the common variants in a region. The bottom row
demonstrates howdata for thosegenotypescanbe
phased using reference population data and how
missing genotypes can be imputed if the haplotype
can be inferred accurately. In some instances,
imputed genotypes may be uncertain.
(B) Fine-mapping with conditional haplotype anal-
ysis. The left-hand side lists genotypes at ten variant
sites (numbered) that define seven common haplo-
types. Each row represents a haplotype, and
genotypes at variant sites are listed in each column.
Assuming that a common variant association is
observed at marker 1, identical associations will be
observed at the markers 2, 3, and 5 because their
genotypes are correlated across haplotypes. In the
first step, haplotypes are grouped by marker 1. The
result is that the seven haplotypes form two
subgroups (indicated by purple and red bars on the
right). The purple group demonstrates association
with disease (right). Including marker 7 breaks the
groups up further into four haplotypes (indicated by
purple, green, blue, and red bars on the far right). By
adding marker 7, differential risk association
between haplotypes is apparent. Whereas the T/G
haplotype confers risk, the T/T haplotype confers
even more risk. Thus marker 1 alone does not
parsimoniously explain all of the risk at that locus.spot between them are often linked over long periods of time and
have high pairwise D0. Those markers can often be grouped into
a set of limited number of common haplotypes (see Figure 2A).
Phasing algorithms can be applied to determine markers in cis
and to define the most likely haplotypes.
Rare alleles generally sit on long haplotypes whereas common
alleles sit on shorter ones. When a mutation first occurs de novo
on a chromosome, it occurs on the background of a single rare
haplotype defined by all markers on that chromosome (see
Figure 1B). Because the de novomutation appeared as a random
event, it initially has no correlation with other markers on that
chromosome (r2 = 0). In initial generations, prior to a recombina-
tion event, the mutation has D0 = 1 with other markers across the
chromosome. But, if the mutation survives generations and
becomes a common allele, repeated recombination events frag-
ment that haplotype and reduce its length. The allele retains high
D0 to only proximate markers that are not separated from it
by a recombination hot spot. As the variant becomes more
frequent, so does the haplotype that it occurs on; over time the
emerging variant develops correlation (r2 > > 0) with the markers
on that short haplotype (see Figure 1C).
Finding Pathogenic Variants, Both Rare and Common
Common variant associations to phenotype are often facile to
find. Their high frequencies allow case-control studies to be
adequately powered to detect even modest effects. Their highr2 to other proximate common variants allows for association
signals to be discovered by genotyping the marker itself or
other nearby correlated markers. But mapping those associated
variants to the specific causal variant that functionally influences
disease risk can be challenging because the statistical signals
invoked by intercorrelated variants are difficult to disentangle.
On the other hand, individual rare variant associations are
challenging to find. Their low frequency renders current cohorts
underpowered to detect all but the strongest effects, and lack of
correlation to other markers often prevents them from being
picked up by standard genotyping marker panels. But, once a
rare associated variant is observed, mapping the causal rare
variants is relatively facile because recent ancestry is likely to
limit the number of intercorrelated markers.
Functional Properties of Pathogenic Variants, Both Rare
and Common
Because common alleles tend to be ancient, they have weath-
ered the influences of purifying negative selection. Therefore,
common variants that influence disease risk are likely to have
functionally modest effects that are compatible with their high
population frequency. There are two possibilities outlined by
Kruyokov et al. that might allow for this (Kryukov et al., 2007).
First, common variants that are medically detrimental act subtly
or specifically to confer disease without altering evolutionary
fitness. As an example, consider a variant that confers risk ofCell 147, September 30, 2011 ª2011 Elsevier Inc. 59
Box 1. Glossary
Associated allele: An allele that, in a genetic study, is observed to
have differential allele frequencies in cases compared to controls.
The presence of an association suggests that it, or some other variant
in LD, is influencing disease susceptibility.
Causal allele: The functional allele that influences disease suscepti-
bility and explains the observed associated allele.
Common alleles: Alleles with a high population frequency, typically
defined as >1%. Standard marker panels can often be used to iden-
tify common allele associations.
Rare alleles: Alleles with a lower allele frequency of <1%. These
alleles can be polymorphic in the population being seen in multiple
distantly related individuals; alternately they might be alleles that
are private to an individual or seen in a small number of closely related
individuals.
De novo mutations: A mutation that has occurred in an individual
and that was not inherited from a parent. These mutations are initially
private. If a de novo mutation is passed on and persists through
generations, it can become a polymorphic allele.
Linkage disequilibrium (LD): Two polymorphic loci are in LD when
they are colocated, and alleles at those loci are distributed nonran-
domly with respect to each other on chromosomes in the population.
Linkage disequilibrium is present when recombination events
between two loci occur infrequently. Two metrics for LD are r2
and D0 (see Figure 1A).
Recombination hot spots: Individual regionswithin the genome that
have frequent recombination events.
Negative selection: Selection acting to remove new deleterious
mutations that reduces evolutionary fitness of an individual. Also
known as purifying selection.
Positive selection: Selection acting to propagate new advanta-
geous mutations that increase evolutionary fitness of an individual.
Balancing selection: Selection acting to increase allelic variability at
a locus.
Genotype imputation: A statistical technique to infer missing geno-
types in a set of individuals using a reference panel of genotyped indi-
viduals. Imputation exploits LD between genotyped and ungeno-
typed variants.
Genome-wide significance: A level of statistical significance
typically used to establish association for a common variant in
genome-wide association studies (p = 5 3 108), which assumes
that there are1,000,000 effective independent tests genome-wide.
Stratification: A genetic confounder if there are differences in the
ancestral origin of cases and controls. The resulting systematic allele
frequency differences can result in false-positive associations.
Genomic inflation factor (l): The ratio of themedian of the observed
chi-square statistics for an association study and the expected
median chi-square statistic. If there is stratification, the test statistic
is inflated, causing the genomic inflation factor to be substantially
greater than 1, resulting in inappropriately significant p values.
Fine-mapping: The use of dense genotyping data around an associ-
ated allele to identify the causal allele(s) to account for the observed
statistical signal in the region.
Second-generation sequencing: Recent sequencing technologies
not using Sanger chemistry that characteristically generate many
short read sequences.
Targeted region: The region of the genome selected for a sequenc-
ing experiment.
Whole-genome sequencing: A sequencing experiment where the
full 3 GBp of whole genome is sequenced. Does not require
DNA capture. For most medical genetic studies, the sequencing
Box 1. Continued
data are not reassembled but mapped to a reference genome
sequence.
Whole-exome sequencing: A sequencing experiment where the
protein-coding sequences of all known genes are targeted, captured,
and sequenced (30 Mbp).
Coverage: In a sequencing experiment, coverage at a genomic posi-
tion is the total number of reads mapped to that position.
60 Cell 147, September 30, 2011 ª2011 Elsevier Inc.addiction to tobacco (Thorgeirsson et al., 2008). Such a variant
might have little impact on survival historically but might have
specific neuropsychiatric effects that mediate the risk of 21st
century diseases such as lung cancer or coronary artery disease
that play a role later in life after reproduction. Second, forces that
select specifically for these common variants counteract their
medically detrimental qualities; the variant, although causing
disease, also offers evolutionary benefit simultaneously. For ex-
ample, common ApoL1 variants that confer high risk of chronic
kidney disease in African Americans protect from Trypanosoma
brucei rhodesiense infection at the same time (Genovese et al.,
2010).
Because rare alleles are typically more recent, they may not
have been subjected to the same negative selective pressures
yet and may include among them more relatively deleterious
mutations. Rare alleles therefore often are enriched for those
variants more likely to have more dramatic functional conse-
quences. This is supported by data indicating that rare deletions
are more likely than more common deletions to remove entire
genes, exons, promotors, or stop codons (Conrad et al., 2010).
Similarly, rare variants are twice as likely as common ones
to be nonsynonymous (1000 Genomes Project Consortium,
2010). Because rare variants are relatively unrestricted in terms
of their functional impact in general, a subset of rare pathogenic
variants with large effect might offer more obvious insight about
disease mechanism.
Common Variants
Detecting Common Variants with High-Throughput SNP
Arrays
High-throughput genotyping of standard marker panels of
common single-nucleotide polymorphisms (SNPs) has become
possiblewithmicroarrays (Gunderson et al., 2005). Their applica-
tion to large case-control sample collections has facilitated
detection of even the most modest risk alleles, with odds ratios
of 1.1 or less. There are a finite number of common variants
present in the general population, i.e., <6 million are estimated
in European populations (1000 Genomes Project Consortium,
2010). But nearby common SNPs are in LD with one another
and define a limited number of haplotypes (see Figure 2A), so
the effective number of independent variants is much fewer.
Thus, genotyping a limited number of common variants
genome-wide has the effect of coveringmanymore common vari-
ants. In European populations, the Affymetrix 5.0 array with 440K
SNPs has r2 > 0.8 for 57%of common variants, and the Affymetrix
6.0 array with roughly double the number of SNPs (900K) has
r2 > 0.8 for 66% of common variants (Bhangale et al., 2008).
Genome-wide genotyping also allows investigators to use
imputation to estimate genotypes of markers not directly geno-
typed; in doing so, it becomes possible to combine samples
genotyped on different platforms. Probabilistic multipoint impu-
tation algorithms, using a limited number of genotyped common
variants, can determine the genotypes of ungenotyped common
variants by comparing to a reference panel of comprehensively
genotyped individuals (see Figure 2A). Most of these methods
currently use probabilistic Hidden Markov Model approaches
to infer the local LD structure (Browning, 2008; de Bakker
et al., 2008).
Selecting Populations for Study
Initial efforts to map complex traits emphasized selected iso-
lated populations, for example the Finish populations (Peltonen
et al., 2000). These populations can offer the advantage of
increased inbreeding, more uniform genetic and environmental
backgrounds, detailed genealogical records, availability of intact
extended families, and longer LD intervals. Populations that have
undergone rapid population expansion may be of particular use
because LD intervals are longer. The most successful validation
of this approach is represented by deCODE genetics and their
study of a wide-range of complex diseases in Iceland.
Now, investigators are increasingly focused on the inclusion of
individuals frommultiple ethnic backgrounds in order to enhance
the ability of studies to discover risk alleles with variable allele
frequencies across different backgrounds (Rosenberg et al.,
2010). Different ethnic backgrounds might highlight different
mechanisms of disease pathogenesis, including differences in
environmental exposures, as well as reflect different degrees
of genetic diversity and LD patterns. A striking example of this
is the discovery of an IL18B variant that predicts response to
hepatitis C treatment with equivalent effect in European, African,
and Hispanic American patients; allele frequency differences of
the variant explain about half of the differences in treatment
response across populations (Ge et al., 2009).
Genome-wide Association Studies
In a case-control genome-wide association study (GWAS),
samples are genotyped for a set of 100,000–2,000,000 markers;
case and control allele frequencies are compared directly to each
other. Statistical significance is assessedwith a simple 23 2 chi-
square test or with logistic regression when genotypes are prob-
abilistic (e.g., from imputation).
Critical to the success of GWAS has been the application of
stringent statistical significance thresholds that result in repro-
ducible associations that account for the large number of simul-
taneous tests (Risch and Merikangas, 1996). Testing for com-
mon variant associations throughout the genome represents
1 million independent tests (Hoggart et al., 2008). Thus investi-
gators routinely use a genome-wide significance threshold
representing a Bonferoni correction for multiple tests (p = 0.05/
106 = 5 3 108).
Because effect sizes for most common variants are modest,
large sample sizes and careful adjustment for subtle technical
artifacts that can easily obscure results or produce false-positive
associations are of paramount importance (Balding, 2006; Clay-
ton et al., 2005; McCarthy et al., 2008). The genomic inflation
factor is an important metric that indicates the extent of inflation
due to stratification and other technical confounders. Fortu-itously, the strength of genome-wide genotyping goes beyond
simply measuring case-control allele frequency differences
throughout the genome. It also allows investigators to look at
patterns in the genotyping data to identify key technical
confounders. For instance, patterns of excessive ‘‘missing’’
genotype data for an individual indicate that intensity data could
not be clustered into genotype, likely as a function of low DNA
quality or concentration. Another key confounder is population
stratification, that is the presence of the systematic allele fre-
quency differences observed in a population as a consequence
of ancestry rather than case-control status. As a dramatic
example, Campbell et al. showed, even in studies using only
European populations, that not carefully adjusting for an individ-
ual’s country of origin results in a highly statistically significant
false-positive association for height at a lactase SNP (Campbell
et al., 2005). Genome-wide genotype data allow investigators
to identify and correct for case-control population stratification.
Once markers are identified as having statistically significant
allele frequency differences in cases and controls, they are
ideally replicated in independent populations. Replicating in an
independent population not only adds statistical confidence to
the results but also adds confidence that the results of the initial
study are not the consequence of technical confounding or strat-
ification.
Identifying an associated marker rarely clarifies whether the
marker itself is the functional allele that causes altered disease
susceptibility. The observed association at a marker might be
the result of an underlying causal allele with high r2 with the asso-
ciated variant, a rare functional allele on a haplotypic back-
ground shared with the associated variant, or multiple functional
alleles that cause an apparent association. Nevertheless, the
causal alleles must closely correlate and be in LD with associ-
ated variants.
Fine-Mapping Common Variant Loci
Dense genotyping of markers in the region, followed by fine-
mapping, can identify the causal allele, or at least reduce the
number of potential candidates. The underlying assumption is
that the causal allele will most parsimoniously explain the entirety
of the evidence of association. In many instances, however, fine-
mapping is complicated if the association is not being driven by
a marker that has been genotyped; in those instances, it might
be possible to identify a risk haplotype defined by genotyped
markers and to then sequence selected individuals to identify
the causal allele. Thus in order to fine-map effectively, dense
genotyping to include all known markers in the region is key.
Additionally, in many instances there might be multiple causal
alleles, and in order to be powered to detect multiple effects, it
is often necessary to densely genotype a large number of sam-
ples, perhaps more than those used to discover the association.
After densely genotyping a large number of samples, there are
two major statistical tools utilized in fine-mapping common vari-
ants. The first is conditional regression. If a single leadmarker (or
another marker in perfect LD with it) is causal, then applying
conditional regression adjusting for that lead marker should
obviate all other association in the region. The second statistical
tool is conditional haplotypeanalysis (Figure2B).With conditional
haplotype analyses, investigators start with data from a subset of
the genotyped markers and phase genotypes to defineCell 147, September 30, 2011 ª2011 Elsevier Inc. 61
haplotypes. If the selected markers are causal, then the defined
haplotypes should parsimoniously explain the risk at that locus.
That is, the addition of additional markers (and thus creation of
more haplotypes) should not explain risk better, and removal of
any marker (and thus removal of haplotypes) should reduce the
explained risk. With both approaches, if the causal allele is in
perfect LD (r2 = 1) with other markers, then distinguishing
between statistically identical associations may not be possible.
One striking example of fine-mapping was an effort by Pereyra
et al. where they used GWAS to demonstrate that multiple
HLA-B classical alleles are associated with long-term viral load
control in HIV-infected individuals (Pereyra et al., 2010). Then,
with conditional haplotype analysis, they demonstrated that
allelic risk was best defined by amino acid variation at a few sites
along the binding groove of HLA-B.
Data from multiple ethnic populations may be particularly
useful to fine-map associations (Rosenberg et al., 2010). Ideally
a single allele might explain risk across multiple ethnic groups.
This approach is effective only if the same causal allele is present
with a high allele frequency in both, and there are ethnic differ-
ences in local LD structure. The inclusion of African populations
might be particularly useful because LD patterns are generally
shorter. This approach might be complicated if multiple different
alleles in populations influence disease susceptibility within the
same locus. Adrianto et al. looked at SNPs associated with
systemic lupus erythematosus (SLE) spanning the TNFAIP3
gene (Adrianto et al., 2011). When they looked at markers asso-
ciated in Asian and European populations, they were able to fine-
map the associated region from a span of 100 kb to 50 kb.
Subsequent sequencing identified a novel AA > T single base
pair deletion polymorphism that acts to disrupt an NF-kb binding
site. This single variant explained the associated risk of the locus.
Rare Variants
It is possible that associated rare variants for complex diseases
will be more facile to fine-map and to evaluate for functional
impact. The discovery of a rare variant near a common variant
might be particularly informative. A rare variant that clearly
impacts one of the candidate genes implicated by a common
variant might clarify which of the candidate genes is pathogenic.
Furthermore, the rare variant’s function might offer clues about
the mechanism of the common variant. There have been several
examples of this phenomena reported in the literature already.
Common alleles associated with type II diabetes are near five
genes, PPARG, HNF1A, KCNJ11,WFS1, and HNF1B, that have
rare mutations that cause familial forms of diabetes (Voight et al.,
2010). Similarly, 18 of the 95 known common variants associated
with serum lipid levels are near genes that have been implicated
in monogenic lipid disorders (Teslovich et al., 2010). Indeed
studies to find rare coding variants near common risk loci have
already shown success in type I diabetes (Nejentsev et al.,
2009), age-related macular degeneration (S.R. and J. Seddon,
unpublisheddata), andCrohn’sdisease (Momozawaet al., 2011).
The extent to which rare variants explain complex disease
susceptibility in general remains an open question. It has been
speculated that the gap between the heritability explained by
known common variants and that which might be predicted
from family studies might be explained by rare variants (Bansal62 Cell 147, September 30, 2011 ª2011 Elsevier Inc.et al., 2010), and that even many observed common variant
associations might be the consequence of functional undiscov-
ered rare variants (Anderson et al., 2011; Dickson et al., 2010).
Other investigators have suggested that undiscovered common
variants themselves might explain much of that missing herita-
bility (Purcell et al., 2009; Yang et al., 2010).
Identifying Rare Variants with High-Throughput
Sequencing
Advances in DNA capture and sequencing technology have
greatly facilitated targeted, exome, and whole-genome se-
quencing (Maxmen, 2011; Ng et al., 2010) and have in the
process enhanced the search for rare variants. Whereas the
cost of sequencing is rapidly dropping, the computational and
statistical challenges to rapidly aligning sequences to reference
sequences, separating variant calls (SNPs, indels, and structural
variants) from sequencing artifact, data storage, and establish-
ing associations are mounting (McKenna et al., 2010).
Second-generation sequencing technologies have now come
online and are distinct from prior approaches in that they do not
use Sanger chemistry and are characterized by high sequencing
yield with shorter reads (Shendure and Ji, 2008). The Illumina
HiSeq 2000 system, for example, generates >1 billion 100 bp
paired-end useable reads per run. Efficiently mapping a large
volume of short reads to the reference genome accurately has
been an important area of methodological progress (Li and
Homer, 2010). Look-up (or hash-table) based methods map
reads quickly but are not as accurate as less-efficient align-
ment-based methods. Accurate alignment is especially impor-
tant in regions with short insertions or deletions (indels); poor
alignment in such regions can result in false-positive SNP
calls and false-negative indel calls. Repetitive genomic regions
and regions with homology can be challenging to map and,
in some instances, may not be possible to query effectively.
Paired-end sequencing generates two sequence reads from
opposite ends of the same contiguous genomic fragment and
helps overcome some of these alignment issues.
To sensitively and accurately call a heterozygote nonreference
base, a minimum of 203 coverage is necessary to overcome
the uncertainty resulting from sampling short sequence reads
across a diploid genome. Additional coveragemay be necessary
to compensate for random and nonrandom sequencing error,
which may vary across technologies. Even with a high-coverage
sequencing experiment, the coverage is typically nonuniform
across the targeted region. Nonuniform coverage can be related
to biases in DNA capture technologies, in unequal pooling of am-
plicon products from different genomic regions or individuals,
and in intrinsic sequence properties (Harismendy et al., 2009).
Careful experimental technique and sample normalization can
minimize some biases in coverage. Average coverage of an
experiment is thus not as useful of a metric as is the percentage
of target genomic region achieving more than a prespecified
coverage threshold. A set of independently genotyped SNPs to
verify sequence-based genotype calls and assess the accuracy
of sequencing studies is useful to confirm accuracy.
Sequencing can be applied to a set of samples to discover
variants or to genotype variants. For variant discovery, sequence
data can be pooled across multiple samples to boost power to
detect a nonreference base. After application of sequencing to
Figure 3. Power to Find Rare Variants and
Burden Testing
(A) Power to find rare variants. Here is a plot of 80%
power to discover rare associated alleles at p <
107 and p < 1011 for cohorts of both 500 and
5000 cases and controls. The control allele fre-
quency and odds ratio (OR) are plotted along the
x axis and the y axis, respectively. Diagonal lines
indicate corresponding case allele frequencies.
(B) Burden testing. Here data from sequenced
cases (top) and controls (bottom) are depicted
around a gene of interest. Each horizontal line
represents an individual. Variants are shown as
red Xs. Certain variants are rare (i.e., seen once),
and others are more common (vertical line). In this
example, the case variants within the candidate
gene (arrow at bottom and blue shading) are seen
more frequently than in controls. If common vari-
ants are excluded, there are five case chromo-
somes with a rare variant compared to one control
chromosome. This pattern of enrichment is not
evident outside the gene. A burden test of asso-
ciation for rare variants within the gene might be
statistically significant.discover rare variants, confirming the presence of the variant in
discovery samples with TaqMan or capillary electrophoresis
sequencing is useful before exploring in independent samples
to establish disease association.
Power Considerations and Significance Testing
One of the challenges to establishing a rare variant disease
association is that in any given study, few variants are observed.
Therefore, genetic studies are more poorly powered to detect
a rare SNP association than they are to detect more common
association with the same effect size (see Figure 3). Thus to
detect associations at the same statistical threshold, sample
collections larger than those currently used might be necessary.
Establishing association of de novo or private mutations may not
be possible at all because they may be seen only once in an
entire study.
For rare variant associations, the field has not yet defined
accepted standards for statistical significance that account for
the burden of multiple hypothesis testing. Because there are
many more rare variants than common ones, and they are not
typically intercorrelated with each other, a more stringent
threshold may be necessary than applied for common variants.
One conservative approach is to correct for the total number of
bases genome-wide, i.e., p = 0.05/3 3 109  1011 as a signifi-
cance threshold. Most recent studies have limited themselves to
exomes or to a subset of targeted genes; in these instances the
multiple-hypothesis testing burden might be significantly less.
But with spectre of genetic studies with genome sequencing in
the very near future, this conservative threshold may ultimately
turn out to be appropriate.
Despite limitations in power and the need for achieving greater
significance, rare variant associations with strong effects might
be imminently detectable. For instance, as part of a genome-
wide study, Holm et al. were able to identify a rare variant for
sick sinus syndrome (Holm et al., 2011); the coding variant that
explained the association was highly statistically significant in
a modestly sized cohort as it had such a large effect size (odds
ratio [OR] > 12). One strategy to further enhance the prospects
of discovery is to identify those individuals most likely to havehighly penetrant rare mutations. For example, individuals with
younger onset or more severe disease, those with familial forms
of disease, or those individuals that have disease despite a lack
of other clinical or genetic risk factors might be promising candi-
dates for rare variant association studies.
Burden Testing
If a genomic region is critical to disease pathogenesis, rare muta-
tions may modulate disease susceptibility. Then, many affected
individuals may have rare mutations more frequently in that
region, though themutationsmay be different from and unrelated
to one another. This concept has sparked interest in the genetics
community, and workers in statistical genetics have devised
strategies to examine rare variants in aggregate across a target
region (Bansal et al., 2010). These ‘‘burden’’ tests assesswhether
rare variants within a specific region are distributed in a non-
random way, suggesting that they might be playing a role in dis-
ease pathogenesis (see Figure 3B). For example, a simple burden
test might assess whether cases are enriched for rare variants
compared to controls. More sophisticated tests account for the
possibility that the region contains both protective and risk-
conferringmutations. The target regionmight be a specific subre-
gion of a gene, an entire gene transcript, or the entire genome.
This approach is an important alternative to the challenging
task of establishing the association of individual rare variants;
using these approaches to test multiple variants simultaneously
might enhance power over testing individual variants. For
instance, a burden test might be able to identify nonrandom
distributions even of private mutations.
In an early application of rare variant burden testing, Cohen
et al. examined individuals from the general population with
high and low HDL levels and assessed the burden of rare varia-
tion in three candidate genes known to harbor Mendelian muta-
tions that cause familial low serum high-density lipoprotein (HDL)
levels (Cohen et al., 2004). They found that individuals with low
HDL levels were significantly more likely to contain rare nonsy-
nonymous mutations than those with high HDL levels; of the
low HDL individuals, 16% had at least one rare mutation,
compared to 2% of high HDL individuals. This suggestedCell 147, September 30, 2011 ª2011 Elsevier Inc. 63
strongly that for individuals with low HDL levels, 14% of them
may have mutations in these three genes mediating phenotype.
The idea of comparing the proportion of case individuals with
rare alleles to control individuals with rare alleles was formalized
into a statistical test, the ‘‘Cohort Allelic Sums Test’’ (CAST)
(Morgenthaler and Thilly, 2007). Subsequently, more sophisti-
cated tests have been proposed that allow investigators to
combine association testing of rare and common alleles by either
testing for association together in multivariate tests (Li and Leal,
2008) or combining rare and common alleles weighted inversely
to their allele frequency (Madsen and Browning, 2009).
One very powerful way of enhancing burden testing is to filter
variants that aremore likely to be causal from those that are likely
not to be causal. For example, investigators may focus their
studies on nonsynonymous alleles. Alternative approaches
might include filtering variants based on sequence conservation
properties or other bioinformatics approaches (Adzhubei et al.,
2010; Ng and Henikoff, 2003).
A successful test, where statistical significance is obtained,
can be used to argue that (1) the tested rare variants play a
role in a specific disease, and (2) the target region tested plays
an important role in disease pathology. But, it fails to implicate
specific variants, and ambiguity about the causal variants might
remain. For example, if rare variants are enriched in a gene 2-fold
in cases compared to controls, then roughly half the variants
seen in cases might be pathogenic, but the other half are part
of the background distribution of rare variation in that gene and
may not influence disease risk.
Structural Variants
Rare structural variants have gained recent interest; the
frequency and size of structural variants have repeatedly shown
enrichment in schizophrenia and other neuropscychiatric dis-
ease (International Schizophrenia Consortium, 2008; Sebat
et al., 2007;Walshet al., 2008).However, except for a fewspecific
regions such as 22q11 and 16p11, most rare events have uncer-
tain pathogenecity. For instance, although the rates of >100 kb
deletion events are significantly increased in cases compared
to controls, there is great uncertainty as to which individual
events are pathogenic andwhich ones are nonpathogenic events
that might occur in the general healthy population. This is analo-
gous to the circumstance that might occur with a statistically
significant burden test for point mutations, described above.
Extended Haplotypes
As previously discussed, many rare variants are recent and
occur on extended haplotypes that can be identified using
common variant markers. Thus GWAS datasets may be used
to identify long-range haplotypes based on common markers
and to then assess whether they are associated with phenotype.
If this is the case, the phenotypic association might be driven by
a highly penetrant rare variant. We used this approach to find an
extended haplotype in the CFH gene that conferred high risk of
age-related macular degeneration; subsequent sequencing
identified the causal mutation to be an argenine to cysteine
change in the C terminus of the protein (S.R. and J. Seddon,
unpublished data).
This approach might be most effective in isolated populations
where reduced genetic diversity and founder effects make it
possible to identify long-range haplotypes (Kong et al., 2008).64 Cell 147, September 30, 2011 ª2011 Elsevier Inc.One recently published method to identify long and rare haplo-
types, and to then test for association to phenotype, has been
successfully applied to multiple phenotypes in out-bred popula-
tions (Gusev et al., 2011).
From Variants to Function
Translating rare and common variants to function can be chal-
lenging. In many instances the presence of an association
does not clarify which variants are functionally causing disease
susceptibility. For common variants, fine-mapping might be
stymied by local LD. For rare variants, burden testing might be
able to identify a genomic region enriched for rare variants but
may not be able to specifically distinguish the individual causal
rare variants from spurious nonpathogenic variants. Here we
describe broad approaches that might be pursued to clarify
pathogenic functions and causality, in the absence of genetic
mapping that has clearly identified a single causal variant.
Evaluating Nonsynonymous Coding Variants
About 1% of the genome consists of protein-coding sequences.
Variants in this portion of the genome are potentially the most
amenable to follow up by biochemical characterization of the
protein product in vitro, characterization in cell lines, or evalua-
tion in transgenic model organisms. Only a minority of associ-
ated common variants can be explained by a nonsynonymous
coding variant (10%) (Hindorff et al., 2009). Currently, most
studies of rare variation emphasize nonsynonymous coding vari-
ants; in many cases, noncoding variants are altogether ignored
even if they are sequenced. An important challenge in the field
is to prioritize discovered coding variants for potentially time-
consuming functional follow up.
Computational approaches can be effective at assessing the
degree to which a specific amino acid substitution in a protein,
induced by a variant, might disrupt function. The functional
impact of a substitution can often be estimated by using informa-
tion about sequence conservation at the mutated site from
comparative sequence analysis of a gene with orthologs and pa-
ralogs. If an amino acid site in a protein sequence is functionally
critical, then most de novo mutations are deleterious and are
subject to purifying selection; these sites then are expected to
show little variation. Thus, a nonsynonymous allele from a study
in a highly conserved site is likely to be deleterious. Sequence
conservation in organisms more closely related to human is
particularly informative because more distantly related organ-
isms may have divergent biology and protein function. Many
software tools using these principles to assess coding variants
have now been devised (Cooper and Shendure, 2011). One
example of such a program is Polymorphism Phenotyping 2 (or
PolyPhen 2) (Adzhubei et al., 2010). The most predictive features
in this method are the estimated likelihood that the mutant allele
fits the substitution pattern observed in the multiple-sequence
alignment; the evolutionary distance to the organism with a
protein harboring a similar nonsynonymous substitution; and
whether the mutant allele occurs at a site that is hypermutable.
The method uses these features and others, including informa-
tion from the three-dimensional protein structure, to define
a statistical model that includes the probability of disease based
on a catalog of known pathogenic Mendielian mutations. The
functional importance of an amino acid replacement is predicted
from these features based on a naive Bayes classifier. PolyPhen
2 and other related methods demonstrate similar performance in
their ability to predict pathogenic mutations achieving an area
under the curve (AUC) of 75%–80% (Hicks et al., 2011).
Experimental approaches to individually interrogate rare vari-
ants with functional assays can also be very powerful. But, for
an approach to be effective, it is critical that the functional assay
is high throughput, and that it has an assayed function that is
relevant to the phenotype. Otherwise, mutations that affect the
assayed gene function might not in fact be pathogenic. In one
application of this approach, Davis et al. used it to look at indi-
vidual mutations with the TTC21B gene and to show that they
cause human ciliopathies (Davis et al., 2011). First they demon-
strated that a translation-blocking morpholino specific for
TTC21B resulted in gastrulation defects in zebrafish that were
consistent with cilliary dysfunction. Then, when they rese-
quenced TTC21B in a large, clinically diverse ciliopathy cohort
and matched controls, they observed a similar frequency of
rare variants. But, when they tested those rare alleles to identify
those that caused gastrulation defects in zebrafish, they
observed a significant enrichment of functional alleles in cases
compared to controls.
Evaluating Noncoding Variants
Noncoding variants pose a particular challenge to the field
at the moment. The noncoding genome represents 99% of the
genome and at present is poorly annotated (Alexander et al.,
2010). About 10% of the noncoding genome is under purifying
selection, suggesting that they harbor critical processes that if
disrupted could be pathogenic (Davydov et al., 2010). Many
common variants, if they contribute to disease, likely act by im-
pacting the noncoding genome. As one example, an associated
Crohn’s disease SNP in LD with polymorphic deletion overlaps
the IRGM gene promotor and modulates gene expression
(McCarroll et al., 2008). In the last several years, however, several
promising approaches have emerged to evaluate noncoding
variants that might point the way to causality, such as analyzing
sequence conservation, gene expression, and chromatin state.
Sequence Conservation
A computational approach to prioritizing noncoding variants is to
identify those that are at sites with a high degree of sequence
conservation across mammalian organisms and are thus under
purifying negative selection (Cooper et al., 2005; Miller et al.,
2007). These approaches differ from those approaches used to
prioritize coding substitutions, as they can only use nucleotide
sequence similarity. Indeed, investigators have argued that the
conservation information from nucleotide sequences is as
predictive as the information gained by peptide sequence simi-
larity and protein structural features (Cooper et al., 2010). The
value of assessing common variants with sequence conserva-
tion approaches is uncertain, as common variants are presum-
ably not under purifying negative selection. But, rare noncoding
variants that have dramatic effects on disease susceptibility
might be effectively prioritized with this approach.
eQTL Data Can Suggest Causal Genes and Mechanism
Expression quantitative loci (eQTL) are genetic variants that
correlate with the transcript level of a gene (Jansen and Nap,
2001). To date, most reported eQTLs are cis-effects, acting on
nearby genes by encoding variants that modulate promotoractivity, enhancer activity, or mRNA stability. Expression QTL
acting in trans have been largely unexplored thus far. Although
most recently discovered eQTL have been common variants,
there is evidence of rare eQTL also (Montgomery et al., 2011).
Identifying rare eQTL might be challenging given the limited
power of currently sized cohorts. In the future, burden tests
previously described might be able to effectively identify small
genomic regions where rare variants dramatically impact tran-
script levels.
It has been shown that common trait-associated variants have
a significant overlap with eQTL, suggesting the possibility that
many common disease variants act by altering transcript levels
(Nicolae et al., 2010). Thus, it might be insightful to assess
whether a specific disease-associated common variant is itself
an eQTL. If it is, then the gene whose transcript is influenced
by the risk allele might be the causal gene. Furthermore, if the
risk allele is increasing the transcript level, then the gene may
increase disease risk by magnifying gene function; alternatively,
if the risk allele reduces transcript level, then the genemay cause
disease by mitigating gene function. A convincing eQTL effect
can be isolated by transfecting constructs with risk haplotype
fragments, as was done to identify the causal variant in the
SORT1 lipid locus (Musunuru et al., 2010). Another compelling
example of an eQTL that influences disease susceptibility is
a type II diabetes-associated variant upstream of the KLF14
transcription factor. Investigators showed that this variant acts
not only as a cis-eQTL influencing KLF14 levels in adipose tissue
but also as a trans-eQTL formany genes regulated byKLF14 that
are important in metabolic traits (Small et al., 2011).
There are a few important caveats about this seemingly
straightforward approach.
First, because eQTL are spread throughout the genome,
spurious overlap between disease-associated variants and
eQTL is possible (Nica et al., 2010). If a risk variant confers risk
by modulating transcript levels, and it is itself causal (or in LD
with the causal variant), then it should also be consistent with
the strongest eQTL effect in the region. Checking to ensure
that the disease-associated variant is consistent with the stron-
gest eQTL effect itself mitigates the risk of spurious overlap.
However, it is still possible that the causal allele and the stron-
gest eQTL effect are strongly correlated by chance, and that
eQTL association is unrelated to disease risk.
Second, although many eQTL act generically, most are tissue
specific (Dimas et al., 2009; Price et al., 2011). In fact, certain
eQTL may not be detectable unless the cell has responded to
a specific stimulus or stress. In order to understand the tran-
scriptional impact of disease alleles most effectively, identifying
eQTL in the pathogenic tissues is key. Current eQTL databases
are based on a small number of resting cell types, for example
lymphoblastoid cell lines (Stranger et al., 2007). Many important
pathogenic tissues are not easily accessible for eQTL studies. In
the near future, the catalog of available tissues profiled will
expand dramatically with the NIH-sponsored Genotype Tissue
Expression (GTEx) project, aiming to profile >60 separate tissues
(https://commonfund.nih.gov/GTEx/).
Finally, although eQTL data can offer potential in identifying
the likely causal gene and provide hints about mechanism for
common variants, they may not clarify ambiguity about theCell 147, September 30, 2011 ª2011 Elsevier Inc. 65
causal variant if there are multiple variants in LD. Certain variants
may seem more promising, for example structural variants or
SNPs overlapping a regulatory variant. As with disease-associ-
ated common variants, eQTL datasets often face challenges in
fine-mapping signals.
Chromatin Modifications
Identifying regions of the genome that act as regulatory elements
can offer important complementary information to eQTL data
in evaluating noncoding variants. Specific functional regulatory
elements can be identified from genome-wide profiles of key
histone modifications: H3K4me3 marks active promoters;
H3K4me1 marks enhancers; H3K4me2 and most histone acety-
lation mark both promoters and enhancers (Barski et al., 2007;
Heintzman et al., 2007; Wang et al., 2008). Similarly, DNase I
hypersensitive sites also flag open chromatin regions harboring
promoters and enhancers (Sabo et al., 2006). With the advance-
ment of high-throughput sequencing technologies and develop-
ment of techniques such as ChIP-seq (Park, 2009) and DNase-
seq (John et al., 2011), there are mounting public data on
genome-wide chromatin profiles. For instance, histone mark
ChIP-seq and DNase-seq data on over 100 cell lines and tissues
have now been generated through the ENCODE and Roadmap
Epigenomics projects (Bernstein et al., 2010; Birney et al., 2007).
Although computational approaches to identify putative
binding sites based on sequence data alone are nonspecific,
recent reports suggest that the prediction of active regulatory
sites within assayed tissues is possible by including ChIP-seq
and DNase-seq data (Ernst and Kellis, 2010; He et al., 2010;
Pique-Regi et al., 2011; Song et al., 2011). One potential
approach then to prioritize noncoding variants for follow up is
to identify those that are in regions that have been predicted to
be regulatory elements. These variants might, for example,
disrupt or enhance a transcription factor binding at an enhancer
or a promoter. Particularly promising variantsmight be those that
have eQTL activity in the same cell type. Histone mark locations
and DNase hypersensitive sites have been shown to be enriched
near associated variants (Ernst et al., 2011; McDaniell et al.,
2010). A key limitation of this approach is that, like eQTL data,
it requires genome-wide chromatin data from the same or similar
cell types as those that are pathogenic.
Identifying Causal Processes with Integrative Analyses
In many instances where the specific causal variant within a
locus cannot be identified, examination of the genes implicated
may still help to suggest the key underlying functional networks
and pathways that might be active in a disease. For instance,
age-related macular degeneration associations have implicated
the complement pathway without necessarily identifying causal
variants. This task can be challenging in general because for
any given associated allele, 20 or more genes might be impli-
cated by LD, and any of them may harbor the causal mutation.
But despite that, statistically significant connectivity between
genes in different associated loci can often be identified. We
and others have devised strategies to look for functional connec-
tions or similarity between genes across implicated loci. These
networks can predict novel gene loci and offer insight about
disease mechanism. Gene Relationships Across Implicated
Loci (GRAIL) uses >400,000 published scientific PubMed texts
to assess pairwise gene similarity between genes across loci66 Cell 147, September 30, 2011 ª2011 Elsevier Inc.(Raychaudhuri et al., 2009a). In addition to repeatedly showing
highly statistically significant connectivity between genes across
loci in multiple diseases, GRAIL has been used to prospectively
predict and prioritize associated variants (Raychaudhuri et al.,
2009b) and prioritize disease genes within a locus (Beroukhim
et al., 2010). Investigators used a similar approach, Disease
Association Protein-Protein Link Evaluator (DAPPLE) algorithm,
to demonstrate that protein-protein interactions are enriched
among genes within disease loci more than by chance alone
(Rossin et al., 2011). They demonstrated enrichment most con-
vincingly in autoimmunediseases and furthermoredemonstrated
that the enrichment of interactions was often between genes
within the same immune cell types. These networks offer insight
as to how protein products of genes across many loci might be
interacting together to initiate disease. We note importantly
that pathway analyses can be easily confounded, in particular
in neuropsychiatric diseases because there is a correlation
between the sizes of transcripts and the likelihood that they will
have brain function (Raychaudhuri et al., 2010).Conclusions
The advances in genotyping and sequencing technologies over
the last few years have revolutionized genetics. Only a few years
ago, researchers were still tackling the challenges of gene
mapping and discovery of complex diseases. Now we face an
embarrassment of riches in which the ability to map loci has
become quick and reproducible. The next important challenge
is streamlining functional validation, which in most cases is still
a critical bottleneck. Rare variant discovery has the potential to
yield more obviously functional variants with larger effect sizes
because they are less constrained by purifying selection. The
discovery of rare variant associations might shed light on those
loci discovered by common variant mapping. However, strate-
gies to prioritize functional follow-up studies will be key at those
loci where common variants cannot be effectively fine-mapped
or individual rare variants (beyond the presence of case enrich-
ment) cannot be identified. Strategies to use regulatory variants,
chromatin state data, and sequence conservation offer a poten-
tial path forward to prioritize candidate variants.SUPPLEMENTAL INFORMATION
Supplemental Information includes one figure and can be found with this
article online at doi:10.1016/j.cell.2011.09.011.
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